Back to Search
Start Over
NO-HDAC dual inhibitors
- Source :
- European Journal of Medicinal Chemistry. 227:113934
- Publication Year :
- 2022
- Publisher :
- Elsevier BV, 2022.
-
Abstract
- HDAC inhibitors and NO donors have both demonstrated independently broad therapeutic potential in a variety of diseases. Borretto et al. presented the topic of NO-HDAC dual inhibitors for the first time in 2013 as an attractive new topic. Here we collected the general structure of all synthesized NO-HDAC dual inhibitors, lead compounds, synthesis methods and biological features of the most potent dual NO-HDAC inhibitor in each category with the intention of assisting in the synthesis and optimization of new drug-like compounds for diverse diseases. Based on studies done so far, NO-HDAC dual inhibitors have displayed satisfactory results against wound healing (3), heart hypertrophy (3), inflammatory, cardiovascular, neuromuscular illnesses (11a-11e) and cancer (6a-6o, 9a-9d, 10a-10d, 16 and 17). NO-HDAC dual inhibitors can have high therapeutic potential for various diseases due to their new properties, NO properties, HDAC inhibitor properties and also due to the effects of NO on HDAC enzymes.
- Subjects :
- Pharmacology
chemistry.chemical_classification
medicine.drug_class
Chemistry
Synthesis methods
Organic Chemistry
Histone deacetylase inhibitor
Cancer
Antineoplastic Agents
General Medicine
Nitric Oxide
medicine.disease
Histone Deacetylases
No donors
Dual (category theory)
Histone Deacetylase Inhibitors
Enzyme
Drug Discovery
medicine
HDAC inhibitor
Humans
Heart Hypertrophy
Drug Screening Assays, Antitumor
Cell Proliferation
Subjects
Details
- ISSN :
- 02235234
- Volume :
- 227
- Database :
- OpenAIRE
- Journal :
- European Journal of Medicinal Chemistry
- Accession number :
- edsair.doi.dedup.....28a6d8ae5157c76e8d59cbd270e5cb30
- Full Text :
- https://doi.org/10.1016/j.ejmech.2021.113934